-
Zelgen Biopharmaceuticals’ Donafenib Receives NMPA Approval for Thyroid Cancer
•
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced that the supplementary New Drug Application (sNDA) for its Category 1 anti-cancer drug donafenib in locally advanced / metastatic radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) has been approved by the National Medical Products Administration (NMPA). This is the second indication approval for…
-
Siemens Healthineers Q3 2022 Results Show Decline Amid COVID-19 Impact
•
Siemens Healthineers AG (ETR: SHL) released its financial results for the fiscal year Q3 2022 period ending June 30. The company reported global revenues of EUR5,186 million (USD5,279 million) over the three months, marking a 5.7% year-on-year (YOY) decline in constant currency terms. This decline was primarily attributed to a…
-
Chinese Researchers Map Cancer Genomic Alterations in 10,000 Patients
•
A team of Chinese researchers led by Wang Minghui at Sun Yat-sen University has conducted deep next-generation DNA sequencing (NGS) on tumor tissues and matched blood specimens from over 10,000 patients in China using a 450-gene comprehensive assay. The study provides a comprehensive comparison of somatically altered genes, the distribution…
-
Longwood Valley Medtech Partners with J&J MedTech on Digital Surgery Biosystem
•
Beijing-based Longwood Valley Medtech has entered into an in-depth partnership with US major Johnson & Johnson MedTech. The two companies will explore digital innovation, product development, marketing, brand promotion, and more. Their goal is to bolster intelligent and precise clinical solutions for orthopedics and surgeries and create a patient-oriented digital…
-
Elite Pharma Raises RMB100m in Series B Financing for Drug Delivery Tech
•
Shanghai-based Elite Pharmaceutical Technology Inc. has reportedly raised nearly RMB100 million (USD14.8 million) in a Series B financing round, led by Innoval Capital. Hefei Industry Investment and Hefei Innovation Investment also participated in the round. The proceeds will be used for research and development, clinical trials, and the construction of…
-
WuXi ATU Licenses TESSA Technology to Janssen Biotech for AAV Production
•
WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused CTDMO unit of WuXi Apptec, has entered into a licensing agreement with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson. Facilitated by Johnson & Johnson Innovation, the deal allows Janssen Bio to utilize WuXi ATU’s TESSA technology and gain…
-
Medlander Medical Technology’s IPO Raises RMB 1 billion on Shanghai’s STAR Board
•
Medlander Medical Technology Inc., a leading Chinese manufacturer of pelvic floor rehabilitation equipment, has completed an initial public offering (IPO) of 25 million shares priced at RMB40.29 on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). The listing has raised RMB 1 billion (USD148.3 million) for the firm. Company BackgroundFounded…
-
InnoCare Pharma’s Orelabrutinib sNDA Accepted for Marginal Zone Lymphoma
•
InnoCare Pharma (HKG: 9969) announced that a supplemental New Drug Application (sNDA) for its Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib has been accepted for review by the Center for Drug Evaluation (CDE). The Chinese firm is seeking a new indication for patients with relapsed or refractory marginal zone lymphoma. Drug…
